Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: BLCO )

19.57 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BLCO

< Previous 1 2 3 4 5 6 Next >
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch & Lomb Earnings Preview
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
6 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
Earnings Preview: Bausch & Lomb
Via Benzinga
Analyst Ratings for Bausch & Lomb
Via Benzinga
Analyst Ratings for Bausch & Lomb
Via Benzinga
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
From Bausch + Lomb
Via Business Wire
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy... 
Via Benzinga
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)... 
Via Benzinga
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.